These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 21906953)

  • 21. Exploration of SAR regarding glucose moiety in novel C-aryl glucoside inhibitors of SGLT2.
    Park EJ; Kong Y; Lee JS; Lee SH; Lee J
    Bioorg Med Chem Lett; 2011 Jan; 21(2):742-6. PubMed ID: 21193308
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Visualization of mechanism of action, and a further therapeutic potential of ipragliflozin, a selective SGLT2 inhibitor].
    Takasu T; Takakura S; Hamada K
    Nihon Yakurigaku Zasshi; 2016; 148(5):266-271. PubMed ID: 27803440
    [No Abstract]   [Full Text] [Related]  

  • 23. Synthesis and biological evaluation of N-glucosyl indole derivatives as sodium-dependent glucose co-transporter 2 inhibitors.
    Chu KF; Song JS; Chen CT; Yeh TK; Hsieh TC; Huang CY; Wang MH; Wu SH; Yao CH; Chao YS; Lee JC
    Bioorg Chem; 2019 Mar; 83():520-525. PubMed ID: 30469144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design of SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: A History Driven by Biology to Chemistry.
    Cai W; Jiang L; Xie Y; Liu Y; Liu W; Zhao G
    Med Chem; 2015; 11(4):317-28. PubMed ID: 25557661
    [TBL] [Abstract][Full Text] [Related]  

  • 25. O-Spiro C-aryl glucosides as novel sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
    Xu B; Lv B; Feng Y; Xu G; Du J; Welihinda A; Sheng Z; Seed B; Chen Y
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5632-5. PubMed ID: 19700318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 5,5-Difluoro- and 5-Fluoro-5-methyl-hexose-based C-Glucosides as potent and orally bioavailable SGLT1 and SGLT2 dual inhibitors.
    Xu G; Du F; Kuo GH; Xu JZ; Liang Y; Demarest K; Gaul MD
    Bioorg Med Chem Lett; 2020 Sep; 30(17):127387. PubMed ID: 32738984
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent Developments of C-Aryl Glucoside SGLT2 Inhibitors.
    Zhang Y; Liu ZP
    Curr Med Chem; 2016; 23(8):832-49. PubMed ID: 26861002
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, synthesis and biological evaluation of 6-deoxy O-spiroketal C-arylglucosides as novel renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
    Wang Y; Lou Y; Wang J; Li D; Chen H; Zheng T; Xia C; Song X; Dong T; Li J; Li J; Liu H
    Eur J Med Chem; 2019 Oct; 180():398-416. PubMed ID: 31325786
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and biological evaluation of novel C-aryl d-glucofuranosides as sodium-dependent glucose co-transporter 2 inhibitors.
    Lin TS; Liw YW; Song JS; Hsieh TC; Yeh HW; Hsu LC; Lin CJ; Wu SH; Liang PH
    Bioorg Med Chem; 2013 Nov; 21(21):6282-91. PubMed ID: 24071445
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conformationally constrained spiro C-arylglucosides as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
    Lv B; Feng Y; Dong J; Xu M; Xu B; Zhang W; Sheng Z; Welihinda A; Seed B; Chen Y
    ChemMedChem; 2010 Jun; 5(6):827-31. PubMed ID: 20414917
    [No Abstract]   [Full Text] [Related]  

  • 31. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
    Davidson JA; Kuritzky L
    Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modification on the O-glucoside of Sergliflozin-A: A new strategy for SGLT2 inhibitor design.
    Cao X; Zhang W; Yan X; Huang Z; Zhang Z; Wang P; Shen J
    Bioorg Med Chem Lett; 2016 May; 26(9):2170-3. PubMed ID: 27025345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of an oxime-containing C-glucosylarene as a potential inhibitor of sodium-dependent glucose co-transporter 2.
    Yuan MC; Yeh TK; Chen CT; Song JS; Huang YC; Hsieh TC; Huang CY; Huang YL; Wang MH; Wu SH; Yao CH; Chao YS; Lee JC
    Eur J Med Chem; 2018 Jan; 143():611-620. PubMed ID: 29216560
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CoMFA and CoMSIA studies on C-aryl glucoside SGLT2 inhibitors as potential anti-diabetic agents.
    Vyas VK; Bhatt HG; Patel PK; Jalu J; Chintha C; Gupta N; Ghate M
    SAR QSAR Environ Res; 2013; 24(7):519-51. PubMed ID: 23305412
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Renal SGLT2 inhibitors: a new type of oral anti-hyperglycemia drugs].
    Zhang WB; Gong N; Wang YX
    Sheng Li Ke Xue Jin Zhan; 2010 Dec; 41(6):453-6. PubMed ID: 21416966
    [No Abstract]   [Full Text] [Related]  

  • 37. In Vitro Pharmacological Profile of Ipragliflozin, a Sodium Glucose Co-transporter 2 Inhibitor.
    Takasu T; Yokono M; Tahara A; Takakura S
    Biol Pharm Bull; 2019; 42(3):507-511. PubMed ID: 30828082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. N-Glucosides as human sodium-dependent glucose cotransporter 2 (hSGLT2) inhibitors.
    Yamamoto Y; Kawanishi E; Koga Y; Sakamaki S; Sakamoto T; Ueta K; Matsushita Y; Kuriyama C; Tsuda-Tsukimoto M; Nomura S
    Bioorg Med Chem Lett; 2013 Oct; 23(20):5641-5. PubMed ID: 23999047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Invokana (Canagliflozin) as a dual inhibitor of acetylcholinesterase and sodium glucose co-transporter 2: advancement in Alzheimer's disease- diabetes type 2 linkage via an enzoinformatics study.
    Rizvi SM; Shakil S; Biswas D; Shakil S; Shaikh S; Bagga P; Kamal MA
    CNS Neurol Disord Drug Targets; 2014 Apr; 13(3):447-51. PubMed ID: 24059302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.
    Rahelić D; Javor E; Lucijanić T; Skelin M
    Ann Med; 2017 Feb; 49(1):51-62. PubMed ID: 27535028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.